AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38630471 — intervention group
Group type: COMPARATOR
Intervention: Combined IV and oral antibiotics (IV ertapenem 1 g/d for 2 days plus oral levofloxacin 500 mg/d and metronidazole 500 mg 3 times/d for 5 days)
Number of subjects: 582
Study 38630471 — intervention group
Group type: COMPARATOR
Intervention: Comparison of treatment success rates
Number of subjects: 582
Study 38630471 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 582
Study 38630489 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus placebo
Number of subjects: 7758
Study 38630489 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin
Number of subjects: 7758
Study 38630494 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial shunt device
Number of subjects: 621
Study 38630524 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine alone
Number of subjects: 30
Study 38630524 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) and mindfulness meditation (MM) training
Number of subjects: 30
Study 38630524 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intravenous ketamine and CBT/MM
Number of subjects: 30
Study 38630525 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional facemask preoxygenation using normal breathing
Number of subjects: 20
Study 38630525 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified high-flow nasal oxygen, closed-mouth breathing, at 50 l min -1
Number of subjects: 20
Study 38630525 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard nasal cannula, closed-mouth breathing, at 50 l min -1
Number of subjects: 20
Study 38630525 — intervention group
Group type: COMPARATOR
Intervention: Standard nasal cannula
Number of subjects: 20
Study 38630551 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks
Number of subjects: 72
Study 38630781 — intervention group
Group type: EXPERIMENTAL
Intervention: FAP-IL2v (fibroblast activation protein α-targeted IL2 variant) administered intravenously once weekly, starting dose 5 mg, with dose escalation up to 25 mg and various uptitration regimens.
Number of subjects: 61
Study 38630908 — intervention group
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin (2.5 mg/kg) plus pembrolizumab (200 mg)
Number of subjects: 34
Study 38630948 — intervention group
Group type: EXPERIMENTAL
Intervention: High-efficacy disease-modifying treatments (H-DMT, n = 13)
Number of subjects: 22
Study 38630948 — intervention group
Group type: COMPARATOR
Intervention: Lower-efficacy treatment
Number of subjects: 22
Study 38630948 — intervention group
Group type: EXPERIMENTAL
Intervention: High-efficacy disease-modifying treatments (H-DMT)
Number of subjects: 22
Study 38630960 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine participants
Number of subjects: 296
Study 38630960 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 296
Study 38631003 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks for up to 17 cycles)
Number of subjects: 994
Study 38631003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 994
Study 38631003 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 994
Study 38631243 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment and exercise three times/week
Number of subjects: 150
Study 38631243 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 150
Study 38631504 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro fertilization treatment among patients undergoing UTx; 72 autologous single embryo transfers (ETs) occurred in 23 patients who completed at least one ET.
Number of subjects: 31
Study 38631504 — intervention group
Group type: EXPERIMENTAL
Intervention: First embryo transfer (ET) after IVF treatment cycle.
Number of subjects: 31
Study 38631504 — intervention group
Group type: EXPERIMENTAL
Intervention: Second embryo transfer (ET) after IVF treatment cycle.
Number of subjects: 31
Study 38631504 — intervention group
Group type: COMPARATOR
Intervention: Programmed protocols for endometrial preparation (n = 61) vs. natural cycle protocols (n = 9).
Number of subjects: 31
Study 38631504 — intervention group
Group type: COMPARATOR
Intervention: Living donor uteri vs. deceased donor uteri.
Number of subjects: 31
Study 38631504 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttransplant ovarian stimulation.
Number of subjects: 31
Study 38631679 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-MST and targeted doctor's guidance by remote micromessaging
Number of subjects: 100
Study 38631679 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care oral hygiene regimen
Number of subjects: 100
Study 38631712 — intervention group
Group type: EXPERIMENTAL
Intervention: CNCT19 (anti-CD19 CAR T-cell) after myeloablative high-dose chemotherapy and autologous stem cell transplantation (HDT/ASCT)
Number of subjects: 25
Study 38631764 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod (15 mg twice a day)
Number of subjects: 80
Study 38631764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 38631764 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod
Number of subjects: 80
Study 38631826 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg daily
Number of subjects: 66000
Study 38631826 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 150 mg daily
Number of subjects: 66000
Study 38631826 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg with metformin 1.5 g daily
Number of subjects: 66000
Study 38631829 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operative management (NOM)
Number of subjects: 0
Study 38631829 — intervention group
Group type: COMPARATOR
Intervention: Operative management
Number of subjects: 0
Study 38631833 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - exercise sessions consist of alternating brief high-intensity (≥85% of the peak heart rate) for 12 weeks, three times a week.
Number of subjects: 60
Study 38631833 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Exercise (MOD) - exercise sessions for 12 weeks, three times a week.
Number of subjects: 60
Study 38631835 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant
Number of subjects: 20
Study 38631835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 38631835 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant and Placebo
Number of subjects: 20
Study 38631835 — intervention group
Group type: EXPERIMENTAL
Intervention: N-of-1 trials
Number of subjects: 20
Study 38631840 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-reflective decision assistance strategy based on reminders and decision support tools
Number of subjects: 0
Study 38631840 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision information strategy based on knowledge dissemination and reflective decision structure strategy through audit/feedback
Number of subjects: 0
Study 38631840 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-reflective decision assistance strategy)
Number of subjects: 0
Study 38631840 — intervention group
Group type: EXPERIMENTAL
Intervention: All strategies
Number of subjects: 0
Study 38631841 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive use of physical restraints (PR)
Number of subjects: 422
Study 38631841 — intervention group
Group type: COMPARATOR
Intervention: Systematic use of physical restraints (PR)
Number of subjects: 422
Study 38631841 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Restrictive and Systematic PR)
Number of subjects: 422
Study 38631936 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive invasive coronary functional testing
Number of subjects: 0
Study 38632115 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week resistance-exercise intervention supervised by real-time videoconference
Number of subjects: 130
Study 38632117 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operative treatment (antibiotics alone or in combination with percutaneous drainage)
Number of subjects: 116
Study 38632117 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan Hinchey classification IIb
Number of subjects: 116
Study 38632117 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco smoking
Number of subjects: 116
Study 38632117 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of air bubbles inside the abscess
Number of subjects: 116
Study 38632117 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous drainage in patients with abscesses > 5 cm
Number of subjects: 116
Study 38632179 — intervention group
Group type: EXPERIMENTAL
Intervention: REP+CONNECT
Number of subjects: 8
Study 38632179 — intervention group
Group type: COMPARATOR
Intervention: REP-only
Number of subjects: 8
Study 38632179 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIDE program participation
Number of subjects: 8
Study 38632262 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (n = 25)
Number of subjects: 125
Study 38632262 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl glucosamine (n = 24)
Number of subjects: 125
Study 38632262 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous teduglutide (n = 26)
Number of subjects: 125
Study 38632262 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (n = 25)
Number of subjects: 125
Study 38632262 — intervention group
Group type: COMPARATOR
Intervention: Standard care only (n = 25)
Number of subjects: 125
Study 38632279 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal inflammation and cytomegalovirus viraemia
Number of subjects: 0
Study 38632457 — intervention group
Group type: EXPERIMENTAL
Intervention: SPH3127 50 mg
Number of subjects: 122
Study 38632457 — intervention group
Group type: EXPERIMENTAL
Intervention: SPH3127 100 mg
Number of subjects: 122
Study 38632457 — intervention group
Group type: EXPERIMENTAL
Intervention: SPH3127 200 mg
Number of subjects: 122
Study 38632457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 38632501 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG nebulization 10 ml three times daily for at least seven days, with dose escalation from 1760 umol/L to 8817 umol/L.
Number of subjects: 60
Study 38632501 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG nebulization at 8817 umol/L.
Number of subjects: 60
Study 38632501 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG nebulization treatment.
Number of subjects: 60
Study 38632556 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise training intervention
Number of subjects: 146
Study 38632556 — intervention group
Group type: COMPARATOR
Intervention: Attention control (i.e., stretching)
Number of subjects: 146
Study 38632602 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic approach for emergency colorectal surgery
Number of subjects: 0
Study 38632602 — intervention group
Group type: COMPARATOR
Intervention: Open approach for emergency colorectal surgery
Number of subjects: 0
Study 38632603 — intervention group
Group type: EXPERIMENTAL
Intervention: GC-PLUS (full version of Get Connected WebApp)
Number of subjects: 0
Study 38632603 — intervention group
Group type: COMPARATOR
Intervention: GC-TLO (attention-control version of Get Connected WebApp)
Number of subjects: 0
Study 38632647 — intervention group
Group type: EXPERIMENTAL
Intervention: Active theta-burst stimulation (TBS) to the left dorsolateral prefrontal cortex (DLPFC) and the vermis of the cerebellum, 1800 stimuli daily for 4 weeks.
Number of subjects: 90
Study 38632647 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation.
Number of subjects: 90
Study 38632647 — intervention group
Group type: EXPERIMENTAL
Intervention: Active theta-burst stimulation (TBS).
Number of subjects: 90
Study 38632661 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Cardiopulmonary Resuscitation (ECPR) initiated by Helicopter Emergency Medical Services System (HEMS)
Number of subjects: 0
Study 38632661 — intervention group
Group type: COMPARATOR
Intervention: Control group: Treatment by ambulance crew and HEMS without prehospital ECPR capabilities
Number of subjects: 0
Study 38632826 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg subcutaneously every 4 weeks (Q4W)
Number of subjects: 1368
Study 38632826 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg subcutaneously Q4W
Number of subjects: 1368
Study 38632892 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 38
Study 38632892 — intervention group
Group type: COMPARATOR
Intervention: Light touch (control)
Number of subjects: 38
Study 38632977 — intervention group
Group type: EXPERIMENTAL
Intervention: risankizumab
Number of subjects: 0
Study 38633575 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontline systemic therapy at diagnosis or after observation
Number of subjects: 501
Study 38633575 — intervention group
Group type: EXPERIMENTAL
Intervention: MZL-IPI (new prognostic score)
Number of subjects: 501
Study 38633754 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 21
Study 38633754 — intervention group
Group type: COMPARATOR
Intervention: Obesity (baseline)
Number of subjects: 21
Study 38633771 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS)
Number of subjects: 24
Study 38633771 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 24
Study 38633772 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral economics-informed intervention bundle including default scheduling of postpartum PCP appointments and tailored messages.
Number of subjects: 360
Study 38633772 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 360
Study 38633812 — intervention group
Group type: EXPERIMENTAL
Intervention: Transport reimbursement (R)
Number of subjects: 300
Study 38633812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified health education (IHE)
Number of subjects: 300
Study 38633812 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS/Telephone tracing (Te)
Number of subjects: 300
Study 38633812 — intervention group
Group type: EXPERIMENTAL
Intervention: RITe intervention (combined R, IHE, Te)
Number of subjects: 300
Study 38634282 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR alert with individualized LLT recommendations
Number of subjects: 2500
Study 38634282 — intervention group
Group type: COMPARATOR
Intervention: No alert
Number of subjects: 2500
Study 38634282 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR alert (among patients whose clinicians did not dismiss the alert)
Number of subjects: 2500
Study 38634282 — intervention group
Group type: COMPARATOR
Intervention: No alert (among patients whose clinicians did not dismiss the alert)
Number of subjects: 2500
Study 38634292 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II hypertension
Number of subjects: 204
Study 38634292 — intervention group
Group type: COMPARATOR
Intervention: Normal blood pressure (BP)
Number of subjects: 204
Study 38634481 — intervention group
Group type: EXPERIMENTAL
Intervention: BlueWind Implantable Tibial Neuromodulation (iTNM) system
Number of subjects: 151
Study 38634928 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (second-line therapy)
Number of subjects: 836
Study 38635026 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthful Plant-Based Diet Index (hPDI)
Number of subjects: 64655
Study 38635026 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthful Plant-Based Diet Index (uPDI)
Number of subjects: 64655
Study 38635026 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Plant-Based Diet Index (PDI)
Number of subjects: 64655
Study 38635026 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hPDI scores
Number of subjects: 64655
Study 38635060 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependent care theory-based post-surgical home care intervention
Number of subjects: 0
Study 38635115 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication review with follow-up (intervention group)
Number of subjects: 27
Study 38635115 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 27
Study 38635133 — intervention group
Group type: EXPERIMENTAL
Intervention: fNIRS intervention during verbal fluency test
Number of subjects: 62
Study 38635133 — intervention group
Group type: EXPERIMENTAL
Intervention: fNIRS intervention during emotion recall task
Number of subjects: 62
Study 38635133 — intervention group
Group type: COMPARATOR
Intervention: fNIRS intervention
Number of subjects: 62
Study 38635151 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (M-Body)
Number of subjects: 45
Study 38635190 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Depression Prevention program
Number of subjects: 204
Study 38635190 — intervention group
Group type: COMPARATOR
Intervention: Another evidence-based youth depression prevention program
Number of subjects: 204
Study 38635245 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily motion discrimination training in the intact field
Number of subjects: 48
Study 38635245 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily motion discrimination training in the blind field
Number of subjects: 48
Study 38635245 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 48
Study 38635272 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery plus nonoperative management (physical therapy plus medications)
Number of subjects: 178
Study 38635272 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative management only (control)
Number of subjects: 178
Study 38635313 — intervention group
Group type: EXPERIMENTAL
Intervention: In-vehicle multimodal warning (voice warning app combined with LEDs)
Number of subjects: 19
Study 38635313 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 19
Study 38635319 — intervention group
Group type: EXPERIMENTAL
Intervention: Health needs assessment conducted by interprofessional teams of registered nurses, physiotherapists, and occupational therapists over 5 months
Number of subjects: 40
Study 38635319 — intervention group
Group type: EXPERIMENTAL
Intervention: Health needs assessment
Number of subjects: 40
Study 38635319 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative approach with descriptive statistics and correlation coefficients
Number of subjects: 40
Study 38635319 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative approach with thematic analysis
Number of subjects: 40
Study 38635448 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-enriched white light (7000 K)
Number of subjects: 30
Study 38635448 — intervention group
Group type: COMPARATOR
Intervention: Warm white light (2500 K)
Number of subjects: 30
Study 38635448 — intervention group
Group type: COMPARATOR
Intervention: Daytime (rested)
Number of subjects: 30
Study 38635544 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based physical exercise (MBPE) program, twice a week over 12 weeks
Number of subjects: 60
Study 38635544 — intervention group
Group type: COMPARATOR
Intervention: Health education (control group), same duration, number of sessions and frequency as MBPE
Number of subjects: 60
Study 38635558 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-based intervention delivered via smartphone
Number of subjects: 160
Study 38635558 — intervention group
Group type: COMPARATOR
Intervention: CHF education only (Control)
Number of subjects: 160
Study 38635762 — intervention group
Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel)
Number of subjects: 1290
Study 38635932 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg orally once daily for 1 year
Number of subjects: 0
Study 38635932 — intervention group
Group type: COMPARATOR
Intervention: Control group continued active surveillance
Number of subjects: 0
Study 38635932 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide treatment
Number of subjects: 0
Study 38635934 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine with ATR inhibitor berzosertib
Number of subjects: 0
Study 38635934 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 0
Study 38636116 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation exercise
Number of subjects: 74
Study 38636709 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic adjusted radiation dose (GARD)
Number of subjects: 92
Study 38636709 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemo-radiotherapy plus (neo) adjuvant chemotherapy
Number of subjects: 92
Study 38636725 — intervention group
Group type: EXPERIMENTAL
Intervention: DTG/3TC
Number of subjects: 386
Study 38636725 — intervention group
Group type: COMPARATOR
Intervention: DTG plus two nucleoside reverse transcriptase inhibitors (NRTIs)
Number of subjects: 386
Study 38636770 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-dilation for grade 1 or 2 strictures
Number of subjects: 42
Study 38636770 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical repair and/or dilation under anesthesia for grade 3 strictures
Number of subjects: 42
Study 38636770 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative vaginal length
Number of subjects: 42
Study 38636770 — intervention group
Group type: EXPERIMENTAL
Intervention: Stricture severity grading
Number of subjects: 42
Study 38636770 — intervention group
Group type: EXPERIMENTAL
Intervention: History of Mayer-Rokitansky-Küster-Hauser syndrome
Number of subjects: 42
Study 38636770 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of vaginal stricture
Number of subjects: 42
Study 38636818 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence (AI) assessment using the e-Boston Bowel Preparation Scale (e-BBPS)
Number of subjects: 393
Study 38636844 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA
Number of subjects: 61
Study 38636844 — intervention group
Group type: COMPARATOR
Intervention: SFA
Number of subjects: 61
Study 38636849 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual non-contrast abbreviated MRI (NC-AMRI)
Number of subjects: 208
Study 38636849 — intervention group
Group type: COMPARATOR
Intervention: Biannual ultrasound (US)
Number of subjects: 208
Study 38636849 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating US and NC-AMRI at 6-month intervals
Number of subjects: 208